ESR1 and breast carcinoma: We have previously shown that tumor biology in older (>70 years) versus younger primary breast cancer cohorts can be distinguished by immunohistochemistry (IHC) using a panel of biomarkers, including ER, PR, HER2, Ki67, Bcl2, BRCA1, BRCA2, E-Cadherin, EGFR, LKB1, MDM2, MDM4, MUC1, p53, VEGF and cytokeratin markers of luminal and basal disease [4].